Jared M. Fine, PhD
Research Associate, Center for Memory & Aging
About

Education and training: PhD, physiology, University of Minnesota, Minneapolis; MS, University of Minnesota.

Overview/research interests: Development of intranasal drug-delivery technologies for the treatment of neurodegenerative diseases.

Current research activities and funding:

  • Efficacy and biochemical mechanisms of treatment with intranasal deferoxamine and insulin in models of Alzheimer’s and Parkinson’s disease
  • Mechanisms of delivery from the nasal cavity to the brain
Affiliation
positions
  • Research Associate, Neuroscience Research Centers 2006 -
    • Publications While At HealthPartners
    selected publications
    Journal Article
  • Intranasal deferoxamine can improve memory in healthy C57 mice, suggesting a partially non-disease-specific pathway of functional neurologic improvement. 
    Brain and behavior. 2020
  • Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's Disease. 
    Neuroscience Letters. 2020
  • Intranasal coadministration of a diazepam prodrug with a converting enzyme results in rapid absorption of diazepam in rats. 
    Journal of Pharmacology and Experimental Therapeutics. 2019
  • Quantifying intranasally administered deferoxamine in rat brain tissue with mass spectrometry. 
    ACS Chemical Neuroscience. 2019
  • Rescue therapies for seizure emergencies: new modes of administration. 
    Epilepsia. 2018
  • Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease. 
    Journal of the Neurological Sciences. 2017
  • Food consumption and activity levels increase in rats following intranasal Hypocretin-1. 
    Neuroscience Letters. 2016
  • Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. 
    Neuroscience Letters. 2015
  • . 2008;157:908-25]. 
    Neuroscience. 2014
  • Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinsons disease. 
    Brain Research. 2014
  • Intranasal administration of CNS therapeutics to awake mice. 
    Journal of visualized experiments. 2013
  • Detection of postoperative sleep-disordered breathing using a portable monitoring device. 
    Sleep & breathing = Schlaf & Atmung. 2012
  • Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice. 
    Experimental Brain Research. 2012
  • Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. 
    Drug delivery and translational research. 2012
  • Intranasal delivery of growth differentiation factor 5 to the central nervous system. 
    Drug delivery. 2012
  • Production and fate of the sea lamprey migratory pheromone. 
    Fish Physiology and Biochemistry. 2010
  • Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis Neuroscience
    2008
  • Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy Brain
    2008
    • Conference Poster
  • Pharmacokinetics of a diazepam prodrug/enzyme combination following nasal administration in rats for treatment of seizure emergencies [poster]
    2015
  • Detection of deferoxamine using liquid chromatography/mass spectrometry with electrospray ionization [poster]
    2013
  • Intranasally administered deferoxamine induces neuroprotection in a 6-OHDA model of Parkinson's disease [poster]
    2013
  • Intranasally administered deferoxamine induces neuroprotection in a 6-OHDA model of Parkinson's disease [poster]
    2013
  • Intranasal deferoxamine treatment in a rat model of Parkinsons disease: preliminary results [poster]
    2012
  • Intranasal deferoxamine improves memory and decreases GSK3B activity in C57 mice [poster]
    2010
    • Review
  • Mechanisms of intranasal deferoxamine in neurodegenerative and neurovascular disease [review]. 
    Pharmaceuticals (Basel, Switzerland). 2021
    • Abstract
  • Delivery of therapeutics via the intranasal route for the treatment of neurodegenerative diseases [abstract]. 
    Neurotherapeutics. 2015
    • presentations
    Contact
    full name
  • Jared M. Fine, PhD
    • primary email
  • Jared.M.Fine@healthpartners.com
    • located in facility
    Quick Info
     
    Collaboration
    Contact Information